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Executive Summary 
In most common fractures, bone is able to heal itself over a six week time period. 
Catastrophic fractures, however, may require that shards of bone be removed surgically, 
leaving critical size defects in fracture areas that are unable to heal in a reasonable 
amount of time. For this reason, bone is frequently targeted by tissue engineering and 
drug delivery strategies aiming to encourage bone regeneration.  Often, such strategies 
involve scaffolds or implants in combination with cells and/or growth factors. One major 
design requirement in growth factor delivery from such an implant is that it must exhibit 
controlled growth factor release, defined by relatively constant flux over time. 
Additionally, the growth factor must remain in the tissue at an effective concentration 
over the time required for healing. We report on a computational model and analysis of 
the release of Transforming Growth Factor β (TGF-β) from a spherical, collagen-based 
implant with biodegradable polymer-coated layers containing varying concentrations of 
TGF-β. This model, created using COMSOL Multiphysics software, allows for rational 
design of a biodegradable, drug-eluting implant for tissue regeneration. Using such a 
model, it is easily possible to simulate a variety of conditions (such as different numbers 
of layers or different initial concentrations of drug within each layer) in order to achieve 
relatively constant flux and sustain a physiologically effective concentration of the 
growth factor over time. The following simulations were run: non-layered construct with 
uniform growth factor concentration throughout; five-layered sphere with radially 
increasing concentrations; five-layered sphere with radially decreasing concentrations; 
ten-layered sphere with radially increasing concentrations; ten-layered sphere with 
uniform concentration; ten-layered sphere with radially decreasing concentrations. We 
observed that spheres with more layers exhibited a quasi-linear drug release profile, and 
that radially increasing initial growth factor concentration in the layers, such that the 
highest concentration is at the center, results in relatively constant flux. We also show 
that over time, an implant with radially increasing initial TGF-  concentration exhibits 
sustained release within the range of the effective concentration of TGF-  in hyaline 
cartilage. Our model is important because it can be used to design drug delivery devices 
rationally before costly and time-consuming wet-lab experiments are done. Furthermore, 
our model can be extended to a variety of other drug delivery situations which require 
construct degradation coupled with controlled release.     
 
Introduction and Design Objectives 
Although bone has a natural capacity for bone regeneration and growth, events such 
as bone fractures, bone malformation, cancer, or reconstructive cosmetic surgery require 
aided bone generation. Taking bone fractures in particular, 50% of Americans 50 years of 
age or older are at risk for fracture due to osteoporosis or low bone density. Bone 
fractures result in about 6.8 million doctors’ visits each year, costing $30 million dollars a 
day in the United States alone. Therefore quick, simple, and low-cost methods to aid the 
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healing process are of increasing interest for health care professionals and researchers 
alike. 
One method to encourage bone generation is implant technology that stimulates 
surrounding bone growth onto an inserted matrix/scaffold. Tissue-engineering techniques 
have been successful in bone and cartilage regenerative repair due to the relatively low 
vascularization, and thus infrequent elicitation of an immune response. One of the most 
promising implants proposed for bone generation was by Gombotz et al. (1993) who used 
a polymer/DBM (demineralized bone matrix) biodegradable gel. The gel could be 
injected into sights of injury with or without the aid of a biocompatible metal rod to aid 
the bone healing process. As the polymer of the gel degraded, it left a cartilage matrix 
that was slowly replaced by naturally growing bone during healing.  
The gel was composed of 30% weight/volume poly(lactic-co-glycolic-acid), or 
PLGA, and a DBM containing TGF-β. PLGA was used based on its biodegradation rate, 
biocompatibility, mechanical properties, and pharmacokinetic release properties 
(Gombotz 1993).  Transforming Growth Factor-β, TGF-β, is a 25-kD globular protein 
that has been shown in several studies to stimulate osteoblast and osteoclast activity and 
to successfully increase bone growth (Amento 1993). Demineralized bone matrix has also 
been shown to induce cartilage growth and osseous reconstruction (Glowaki 2009). 
For our project we decided to create a computer model that simulated the 
biodegradation and drug release from an implant somewhat similar to that described by 
Gombotz et al. for bone repair. The model encompasses the implant’s interactions with 
the surrounding tissue of cartilage and bone and is run over the entire time required for 
bone healing. 
Our computational model examined the ability of the biodegradable implant to 
administer an effective concentration of TGF-  at a steady rate to a bone fracture site for 
an extended period of time. In order to achieve steady release of growth factor, it is 
necessary to have quasi-constant flux of TGF-β out of the implant. Because of this 
condition, our model differs from the implant described by Gombotz et al. Instead of the 
implant being composed of a PLGA/DBM gel with a homogenous concentration of TGF-
β, our implant is composed of a multi-layered implant, in which collagen gel layers are 
entrapped between thin membranes of plastic (non-gel form) PLGA. We chose to model 
the layers as collagen gel instead of DBM for several reasons. Collagen gel has the same 
effect on bone healing and has been shown to induce natural cartilage growth and bone 
reconstruction like DBM (Glowacki, 2009). Additionally, in order to model 
biodegradation of the implant, the gel must be composed of a material with similar or the 
same properties as the injury site during early healing stages. During the reparative phase 
of bone healing the injury site is filled with hyaline cartilage, which is later mineralized 
to form bone (Glowacki, 2009).  Since cartilage is in large part composed of collagen, we 
chose collagen as our TGF- -containing layer material. 
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Between each membrane is a composition of collagen gel with a specific initial 
concentration of TGF-β. Each layer is uniform (in thickness, collagen content, etc), but 
concentration of TGF-β in the collagen is varied. Thin membranes of plastic PLGA 
covering each collagen layer keep the TGF-β from diffusing into the rest of the implant, 
thereby maintaining the initial concentrations of TGF-  in each layer. During implant 
degradation, the PLGA layer comes in contact with the physiological environment of the 
implant and degrades, thereby releasing TGF-  into the injury site from the collagen 
layer beneath. We modeled the dissolution time of each plastic PLGA membrane using a 
literature-based equation for the biodegradation of a solid PLGA sphere with a diameter 
of 6 mm.  
During implant biodegradation, the collagen gel composite releases TGF-β into the 
surrounding tissue. The initial concentration of TGF-  in each layer of the sphere was 
defined based on a gradient varying from 0.1 mg/ml to 1 mg/ml to obtain quasi-constant 
flux of the therapeutic TGF-β out of the implant. Furthermore, this range encompasses 
the effective dose needed in the implant for maintained therapeutic properties. We 
modeled the implant inserted into a complete fracture in a human femur that typically 
takes 6-9 weeks to heal, but we wanted to show that TGF-  release could be sustained for 
the time needed for the entire implant to degrade. According to the PLGA degradation 
equation, it would take our implant 92.5 days to degrade completely, so we programmed 
COMSOL to simulate a 92.5-day period.  
With this model we aimed to: 
 Determine the optimal initial drug concentration profile within the 
biodegradable implant for quasi-constant flux of drug 
 Computationally model implant biodegradation in order to achieve 
sustained drug delivery well over the time needed for bone repair 
 Ascertain whether or not our design maintains an effective concentration 
of drug in the tissue for a sufficient period of time to induce replacement 
of the hyaline cartilage with bone. 
 
Model Design 
 In order to evaluate the behavior of this biodegradable implant and the drug 
delivery profile, we used COMSOL Multiphysics to generate a simulation of the implant 
degradation and drug release over the time of in vivo bone healing in a typical adult 
human femur. The implant was modeled as a sphere with surrounding hyaline cartilage 
according to the typical healing process of bone. The cartilage was modeled as 2.4 cm 
thick, according to the typical size of an incomplete critical size fracture in a human long 
bone. Surrounding the cartilage on the top and bottom was bone to simulate implantation 
into the bone break. The bone layer was modeled as 0.6 cm thick based on what we 
determined to be a reasonable computational domain. The geometry and size of the 
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implant modeled was chosen after review of the Gombotz patent for this therapy, and 
other related implants for bone repair (Gombotz 1993, King 2001). The spherical 
geometry of the implant and axisymmetry of a human long bone allowed us to use a two-
dimensional axisymmetric model to reduce our simulation’s computation. The geometry 
and dimensions of the computational domain are shown in Figure 1 below. 
 
 
Figure 1. Schematic of computational domain for COMSOL model. 
 
The governing equation for our analysis is: 
 
Note that there is no need to consider convection, due to the relative lack of fluid 
flow in this area of the body.  Also, since our therapeutic agent is a peptide hormone, it is 
not expected to experience a significant rate of degradation in the tissue, allowing the 
reaction term to be ignored.  The left boundary, as indicated, is the axis about which our 
model is axi-symmetric.  The model is symmetric about the bottom boundary and thus is 
set to a zero-flux condition.  The top boundary is also set to zero flux conditions, as a 
negligible amount of drug diffuses that far into the tissue over the time period of our 
computations. The right boundary condition is a zero concentration boundary condition 
because we assume that blood vessels near the injury site will rapidly remove all TGF-  
that diffuses that far away from the implant. Initial conditions include the concentrations 
of drug in each layer of the implant, which will be adjusted accordingly throughout our 
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project in order to determine an arrangement that provides a relatively constant rate of 
flux.  Furthermore, the concentration of TGF-β in the bone and cartilage tissue is 
assumed to be zero initially.  
 The simulation was run over 92.5 days with a time step of 12 hours. The 
simulation time is based on the average time for complete bone repair of an average 
fracture, along with the time it would take for an implant of 6 mm to degrade. We based 
our choice of a 12-hour time step on the effective diffusion of TGF-β and computer 
computational constraints. The time step was constant throughout the simulation to 
capture the effects of the changing implant diameter and amount of drug diffusing from 
each subsequent layer. We used an unstructured mesh with finer mesh closer to the drug 
sphere due to dynamic changes expected near this area. 
 The diffusivity of TGF-β in hyaline cartilage was modeled as 40x10-12m2/s, and in 
bone as 1x10
-6 
m
2
/s, based on literature values for diffusivity values of proteins and 
molecules of similar size in each tissue (Leddy 2003, Nauman 2007, Williams 2007).  A 
reaction term was not included in the governing equation since TGF-β is a ligand that 
binds to cell surface receptors without internalization. Therefore in vivo concentrations 
can be modeled as unaffected by cellular uptake. 
In order to simulate the biodegradation of the implant, the disc was modeled with 
either five or ten layers that dissolved according to the degradation rate of a solid PLGA 
sphere. To simplify the model enough to implement it, we had to assume the entire 
implant was made of PLGA in order to calculate the degradation time of each thin PLGA 
layer. A macro was then programmed to ―dissolve‖ each layer at a specific time 
determined by the biodegradation rate of the polymer PLGA. This was actually done by 
using the macro to change the diffusivity of TGF-  in each collagen layer from zero to 
40x10
-12
 m
2
/s when the neighboring PLGA layer degrades. Therefore, our model is also 
based on the assumption that no TGF-  diffuses through the PLGA layer until it has been 
completely degraded. 
 Since literature values for the biodegradation of our collagen-PLGA layered 
sphere are unavailable, the degradation rate of the polymer was used. This simplification 
is fairly realistic since only the thin polymer layers degrade, leaving behind collagen 
matrix that is replaced by natural hyaline cartilage in the normal bone healing process. 
The biodegradation rate of 50:50 PLGA (50% poly(lactic acid), 50% poly(glycolic acid)) 
in vivo was determined by using the half-life of this polymer from literature along with 
the following equation: 
Nt = N0e 
– λt 
         (1) 
where N0 is the initial mass of the spherical implant, Nt is the quantity that still 
remains and has not yet decayed after a time t, and  λ is a positive number called the 
decay constant of PLGA. Using the known radius of each layer, the volume of the sphere, 
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and the absolute density of PLGA, the time each layer dissolves was determined. For 
detailed calculations see Appendix D. 
Each layer had a different concentration of the TGF-β in order to maintain a semi-
constant flux out of the implant over time and over the change in geometry as the sphere 
shrinks. The initial concentration in each layer of the sphere was defined based on a 
gradient varying from 0.1 mg/ml to 1 mg/ml. As the volume of the sphere shrinks, the 
space will be filled with a collagen gel/matrix according to the natural healing process of 
bone. Therefore the implant’s geometry and drug concentration will vary with time, 
causing a time step change in the tissue/implant interface. 
 
Results and Discussion 
Because the diffusivity values we obtained were not obtained under the same 
experimental conditions we are working with, we conducted a sensitivity analysis to 
determine how much this might affect our results. To measure the sensitivity of 
computation to the diffusivity parameters we used, we used post-processing integration to 
determine the average concentration of TGF-β in the cartilage matrix after varying bone 
and cartilage diffusivity by -20, -10, 0, 10, and 20 percent. Figure 2 below depicts the 
effect of diffusivity values in both bone and cartilage on the average concentration 
values. Clearly, the model is more sensitive to changes in TGF- ’s diffusivity in 
cartilage. For the diffusivity of TGF-  in bone, there is only slight variation. 
 
 
 
 
 
 
 
 
 
Figure 2. Sensitivity of computational model to changes in diffusivity of TGF-  in bone and cartilage 
regions.  
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Next, we analyzed our model by varying the number of layers and the initial 
TGF-  concentration in each layer in order to determine which arrangement provided the 
most constant flux over time. For comparison against our layered spherical implant, we 
used a classic drug-eluting sphere, which was un-layered and loaded with a uniform 
concentration of TGF-beta (black curve in all figures). For our layered model, we tested 
which was most effective: increasing drug concentration from inside to out, maintaining a 
constant drug concentration throughout, or decreasing drug concentration from inside to 
out. Figure 3 illustrates the results of these trials. The homogeneous model releases its 
drug rapidly and in an uncontrolled manner.  While all layered models out-perform the 
homogeneous model, the most constant flux of drug results when concentration decreases 
linearly from the inside of the scaffold to the outside. It is also interesting to note that 
even with constant concentration of drug throughout, our layered implant releases drug in 
a far more controlled manner than traditional methods.  
 
Figure 3. Percentage of the total TGF-beta initially in the implant that has been released versus time.  (A) 
Represents the case where TGF-beta concentration linearly increases as one moves from the inside of the 
sphere to the outside.  (B) Represents the case where TGF-beta concentration remains constant throughout 
the sphere, but layers are still present and separated by impermeable membranes. (C) Represents the case 
where TGF-beta concentration linearly decreases as one moves from the center of the sphere to the outside.  
(D) Represents the case where there are no internal boundaries, i.e. a homogeneous sphere filled with a 
constant concentration of TGF-beta. 
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Furthermore, we hypothesized that increasing the number of layers would further 
control TGF-  release, and the stair-stepping observed in Figure 3 would approach a 
more linear release.  Figure 4 shows the difference in drug release between the increasing 
concentration and decreasing concentration models with both five layers and ten layers.  
One can see that as we double the number of layers, drug release becomes more 
controlled and more linear in nature. 
Figure 4. Percentage of initial scaffold TGF-beta eluted versus time for (A) a ten-layer implant model with 
increasing concentration from the center to the outside of the sphere, (B) a five-layer implant model, also 
set up with a linearly increasing concentration from the inside of the implant to the outside, (C) a ten-layer 
implant model with concentration linearly decreasing from inside to out, and (D) a five-layer implant 
model with concentration linearly decreasing from inside to out. 
Lastly, we sought to determine the effectiveness of this scaffold at delivering our 
drug into the cartilage, and thus achieving its purpose.  Figure 5 shows the concentration 
of TGF-beta in the cartilage for each of the different models.  With the homogenous 
sphere, one observes that there is a rapid initial increase in drug concentration, but the 
majority of drug is eliminated from the system within 40 days.  However, as one adds 
membrane-separated layers, the drug release becomes steadier and drug permeates 
through the cartilage for a longer period of time.  Again, the model of drug concentration 
decreasing from inside to out shows the most sustained cartilage drug concentration, with 
the concentration varying the least throughout the 80 days. This model also performs 
such that it sustains release of TGF-  at concentrations very close to the therapeutic range 
(0.1 µg/ml to 1 µg/ml, as shown by the area between the two horizontal orange lines).   
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Figure 5. Concentration of TGF-beta in the cartilage as a function of time.  (A) represents the situation 
where initial drug concentration in the sphere increases linearly from inside out, (B) where the 
concentration is the same throughout, but layer boundaries are still present, (C) where the concentration 
decreases linearly from the center of the sphere to the surface, and (D) where the sphere has no layers and 
starts with the same drug concentration throughout. Orange lines depict the therapeutic range of 
concentrations for TGF-  (0.1 µg/ml to 1 µg/ml). 
Lastly, we had to compare our model to known experimental results in order to 
demonstrate its validity.  We compared our results to the results of wet lab experiments 
(Gombotz et al, 1993) involving the release of TGF-beta from a mixture of DBM and 
PLGA. These implants were cylindrical—2 mm in diameter and 2 mm thick. 25 µg of 
TGF-beta and a 40 µl solution of radiolabeled TGF-beta were added to the construct 
initially. A gamma counter was used to measure the amount of radiolabeled TGF-beta 
that was released from the scaffold.  These results are summarized in the Figure 6 below.  
11 | P a g e  
 
 
 
 
 
 
 
 
 
Figure 6. Cumulative amount of TGF-beta released from PLG/DBM device over time 
(Gombotz et al, 1993) 
         Our computational results are shown below, in Figure 7. Over similar same time 
points as chosen in the patent summary, we show that the curve shape and percent of 
drug released is fairly comparable.  
 
Figure 7. Cumulative amount of TGF-beta released from spherical implant over 300 hours. 
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 Because our drug delivery construct is conceptually very different from the 
construct in the patent, we did not expect complete correspondence between the patent’s 
reported values and our calculated values. In addition to design differences, we obtained 
diffusivity values from several other sources, so it is reasonable to see large differences 
between our computational results and their experimental results. We do, however, show 
that we obtain a cumulative release curve of similar shape over the same time scale that 
the patent reports. In Figure 7, the reason for the ―jump‖ at 275 hours is the complete 
degradation of the first PLGA diffusion barrier, and therefore release of additional TGF-
beta.  
Conclusion and Design Recommendations 
The results of our computational model show that a layered drug implant can 
deliver TGF-β to a bone injury site in a controlled, linear manner.  Furthermore, our 
model can achieve and sustain physically relevant concentrations of TGF-β in the 
cartilage subdomain.  The layered geometry, when arranged such that the innermost layer 
is the most concentrated and the outermost layer is the least concentrated, achieves a 
pseudo-linear release profile over a ninety day period.  Conversely, when the outermost 
layer is the most concentrated and the innermost layer is the least concentrated, the 
release profile is more hyperbolic, like that of a non layered, homogenous concentration 
implant.  The implant in which concentration decreased from inside to out provided the 
most constant flux and the most sustained release, and  is thus the most desirable for bone 
healing.  Additionally, this implant maintained a therapeutic level for the longest time 
period in comparison to the other implants.   
In the ideal case, there would be a linear concentration gradient of TGF-β such 
that the highest concentration was contained in the center point of the spherical geometry.  
However, our model utilizes a finite number of layers, as it is impossible to manufacture 
an implant with a perfectly continuous TGF-β gradient.  In our investigations, the 
addition of more layers improved the linearity of our TGF-β release profiles.  However, 
because concentrations undergo large and rapid changes at the boundaries between 
internal layers at their respective release times, additional mesh elements would be 
required to accurately compute the concentrations in these regions. Such an addition of 
mesh elements would make the model increasingly computationally intensive.  In the 
future, we would have to weigh the benefits of adding additional layers to get a more 
continuous profile versus the longer computation time, in order to find the optimal 
number of layers to model.   
Another necessary simplification of the ideal situation is the finite release times of 
the layers.  The approximate mass of each layer and degradation times were calculated 
and based on a literature-obtained half-life of PLGA.  We programmed COMSOL to 
―degrade‖ the PLGA membranes stepwise using a macro logic function that changed the 
diffusivities of TGF-β in the layer from zero to that of TGF-β in collagen at specified 
release times.  In the ideal case, the implant would be degrading and releasing drug 
continuously.  There are two ways that the simplification can be brought closer to the 
ideal case.  First, reducing layer thickness would cause release times to be more frequent, 
13 | P a g e  
 
which more closely approximates the ideal case in which very thin layers would be 
sloughed off continuously. Second, one could implement a moving mesh and moving 
internal boundary to model the degradation of the implant. In future studies, both of these 
alternatives would be explored and compared to the stepwise release approach.       
Practical limitations primarily include simplified geometry, estimated diffusivity 
values, control of manufactured layer thickness, and the idealized biodegradation process.  
We have simplified the geometry to a great degree, and could adjust the geometry so as 
to more accurately represent the break. In a medical situation, MRI or CT data could be 
used to obtain the geometry of a typical fracture.  As the precise data for the diffusivities 
of TGF-β in cartilage and bone are not readily available, we would need to execute an 
independent experiment to accurately measure these parameters. In the actual 
manufacturing process, it might be difficult to control the layer thickness over the entire 
sphere with any great precision. Also, because our product only dealt with an idealized 
model, we can only recommend a preliminary manufacturing procedure.  Finally, the 
PLGA degradation process used in this study is assumed to be uniform. In reality, the 
membranes would most likely not degrade uniformly. Rather, the membranes would 
probably develop pores through which TGF-β could ―leak‖ before the entire membrane 
degraded completely.       
In reality, this implant can be manufactured by a stepwise dip-coating process.  
First a spherical core of a high weight percent collagen gel can be constructed containing 
a defined high concentration of TGF-β.  After allowed to cure for an appropriate amount 
of time, a thin plastic layer of PLGA can then be deposited through a similar dip-coating, 
or possible a spin coating process.  This collagen dip-coating, followed by PLGA dip 
coating procedure would then be repeated with specified TGF-β concentrations until the 
predetermined number of layers is achieved. 
 Using COMSOL, we were able to simulate a number of variations of a single 
drug release model. COMSOL helped us gain fundamental understanding of the physics 
of drug diffusion from a biodegradable implant. The software allowed us to show, with 
reasonable certainty, that a layered, biodegradable, drug-eluting implant can achieve 
quasi-constant flux and maintain an effective drug concentration for the entire time 
period required for bone healing.  In a research environment, a computational model such 
as ours could act as a stepping-stone between concept and costly, time-consuming wet-
lab experiments.   
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APPENDIX A – Mathematical Statement of the Problem 
 
Schematic: 
Governing Equation for Mass Transfer – Cylindrical Coordinates 
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Initial Conditions: 
 
- Five-layered sphere with radially decreasing concentration (1.0, 0.8, 0.6, 0.4, 
0.2 mg/ml) 
- Five-layered sphere with radially increasing concentration (0.2, 0.4, 0.6, 0.8, 
1.0 mg/ml) 
- Ten-layered sphere with radially decreasing concentration (1.0, 0.9, 0.8…0.4, 
0.2, 0.1 mg/ml) 
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- Ten-layered sphere with radially increasing concentration (0.1, 0.2, 0.3…0.9, 
1.0 mg/ml) 
- Ten-layered sphere with uniform concentration (0.5 mg/ml) 
- Non-layered sphere with uniform concentration (0.5 mg/ml) 
 
Boundary Conditions: 
 TOP: Zero flux condition 
 RIGHT: Zero concentration condition (assume blood carries away growth factor) 
 BOTTOM: Zero flux condition (due to symmetry) 
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Appendix B- Mesh Convergence: 
 
Figure A-B1. Meshed geometry for 10-layer implant case.  
Note in Figure A-B1 that the entire implant surface must have very fine mesh 
since the implant/tissue interface will be a major site of diffusion, and thus extremely 
important in calculations. These regions should be as non-discretized as possible to 
capture the physical reality as much as possible. The bone-cartilage interface is also 
assumed to be very important, and therefore is given an extra number of mesh elements.  
The bone itself, on the other hand, plays less of a role in TGF-beta diffusion, and thus is 
given a relatively course mesh. 
Next, we performed a mesh convergence analysis to examine whether what extent 
of meshing was necessary to gain the best balance between simulation accuracy and time 
required to complete the simulation.  As the number of mesh elements increases, the 
concentration of drug in the cartilage changes as well.  However, after a certain point, 
similar increases in mesh element number provide only marginal increases in accuracy, 
and can severely add to computation time.  As is apparent from the plot, the optimal 
number of mesh elements is our setup containing 25,175 elements, as there is only a 
slight change in TGF-beta concentration in the ―hyaline cartilage‖ domain upon 
remeshing with more elements. Therefore, we used 25,175 elements for our 
computations. 
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Figure A-B2. Mesh Convergence Analysis – plot of average concentration vs. number of 
mesh elements. 
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Appendix C - Property Values: 
Property values used in our calculations as well as the sources from which they were 
obtained are shown below in Table A-C1: 
Table A-C1. Property values and their sources. 
Property Value Units Source 
Cartilage diffusivity 40*40^-12 m
2
/s (Leddy & Guilak, 
2003) 
Bone diffusivity 1*10^-6 m
2
/s (Nauman, Campbell, 
Lanni, & Anderson, 
2007) 
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Appendix D – Biodegredation Calculations: 
Vo 9.04779E-07 number of layers: 12   
  
  
Absolute Density: 1.34g/cm^3  (from Arnold et al. 2007) 
Layer # Radius Volume of Layer Mass of Layer Deg. Time per layer(days)  Total Deg. Time (days) secs 
1 0.0005 5.23599E-10 0.000701622 44.99981696 161.3226563 1.39E+07 
2 0.001 4.18879E-09 0.005612979 26.32320546 116.3228394 1.01E+07 
3 0.0015 1.41372E-08 0.018943804 18.6766115 89.99963392 7.78E+06 
4 0.002 3.35103E-08 0.044903831 14.48670534 71.32302242 6.16E+06 
5 0.0025 6.54498E-08 0.087702795 11.83650012 56.83631708 4.91E+06 
6 0.003 1.13097E-07 0.15155043 10.00761825 44.99981696 3.89E+06 
7 0.0035 1.79594E-07 0.240656469 8.668993245 34.99219871 3.02E+06 
8 0.004 2.68083E-07 0.359230648 7.646593962 26.32320546 2.27E+06 
9 0.0045 3.81704E-07 0.5114827 6.840111382 18.6766115 1.61E+06 
10 0.005 5.23599E-07 0.701622359 6.1876334 11.83650012 1.02E+06 
11 0.0055 6.9691E-07 0.93385936 5.648866716 5.648866716 4.88E+05 
12 0.006 9.04779E-07 1.212403437 0 0 0.00E+00 
  
  
Layer # Radius Volume of Layer Mass of Layer Degradation Time (days) 
1 0.001 4.18879E-09 0.005612979 44.99981696 
2 0.002 3.35103E-08 0.044903831 26.32320546 
3 0.003 1.13097E-07 0.15155043 18.6766115 
4 0.004 2.68083E-07 0.359230648 14.48670534 
5 0.005 5.23599E-07 0.701622359 11.83650012 
6 0.006 9.04779E-07 1.212403437 0 
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Appendix E – Contour Plot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-E1. Contour plot of computation model, solution at 92.5 days. X and Y scale is 
in meters, and units of scale bar at right are mg/ml.  
 
